Several other driver molecular alterations have been identified in lung adenocarcinoma, including somatic mutations of KRAS, BRAF, STK11, DDR2 and members of the FGFR family, as well as ALK rearrangements [10], [26], [27], [28], [29], [30], [31]. This evidence concerns the gene STK11 and lung adenocarcinoma.